Technetium sestamibi
As of the edition of 20 October 2026, Technetium sestamibi is a small molecule: marketed, first approved in 1990 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Cardiolite
- First approved
- 21 December 1990 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Shine Spect
- Registered trials
- 13, 1 stopped early
- Disease areas
- Heart and blood vessels; Skin and connective tissue; Cancer; Hormones; Nutrition and metabolism; Blood and lymph
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 1 | 1 |
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 4 | 4 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Dupont Merck | Earlier holder | 1990 to now |
| Shine Spect | Acquired holder | 2026 to now |